PRESS RELEASE published on 01/22/2025 at 07:00, 1 year 9 months ago Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US Relief Therapeutics completes strategic transition by selling GOLIKE rights outside the U.S. to Nutrisens, focusing on R&D and licensing for commercialized products. Company receives CHF 1.2 million upfront R&D Relief Therapeutics Licensing GOLIKE Nutrisens
BRIEF published on 12/27/2024 at 07:05, 1 year 10 months ago Relief Therapeutics Updates on Potential Merger with Renexxion Strategic Partnership Biopharmaceuticals Relief Therapeutics Renexxion Merger Gastrointestinal Therapies
BRIEF published on 12/27/2024 at 07:05, 1 year 10 months ago Relief Therapeutics fait le point sur une éventuelle fusion avec Renexxion Partenariat Stratégique Produits Biopharmaceutiques THÉRAPEUTIQUE DE SECOURS Fusion Renexxion Thérapies Gastro-intestinales
PRESS RELEASE published on 12/27/2024 at 07:00, 1 year 10 months ago Relief Therapeutics Provides Update on Potential Transaction with Renexxion Relief Therapeutics provides update on potential reverse merger with Renexxion, focusing on enhancing shareholder value and future growth opportunities in gastrointestinal disorders therapies Merger Biopharmaceutical Relief Therapeutics Clinical-stage Renexxion
BRIEF published on 12/16/2024 at 07:05, 1 year 10 months ago Relief Therapeutics Reports Promising Outcomes from PKU GOLIKE Trial Biopharmaceutical Clinical Trial PKU GOLIKE Phenylketonuria Metabolic Control
BRIEF published on 12/16/2024 at 07:05, 1 year 10 months ago Relief Therapeutics annonce des résultats prometteurs de l'essai GOLIKE sur la PKU Biopharmaceutique Essai Clinique PKU GOLIKE Phénylcétonurie Contrôle Métabolique
PRESS RELEASE published on 12/16/2024 at 07:00, 1 year 10 months ago Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial Relief Therapeutics announces final readout of PKU GOLIKE clinical trial showing superior metabolic control during prolonged fasting in PKU patients. Results aim to promote awareness and adoption of PKU GOLIKE Clinical Trial Relief Therapeutics PKU GOLIKE Phenylketonuria Metabolic Control
BRIEF published on 12/13/2024 at 23:05, 1 year 10 months ago Relief Therapeutics to End SEC Reporting Obligations with Form 15F Filing OTCQB SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F
BRIEF published on 12/13/2024 at 23:05, 1 year 10 months ago Relief Therapeutics va mettre fin à ses obligations de déclaration auprès de la SEC avec le dépôt du formulaire 15F OTCQB Bourse Suisse SIX THÉRAPEUTIQUE DE SECOURS Formulaire 15F Rapports De La SEC
PRESS RELEASE published on 12/13/2024 at 23:00, 1 year 10 months ago Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Relief Therapeutics announces filing of Form 15F to terminate SEC reporting obligations, maintaining listing on SIX Swiss Exchange and U.S. over-the-counter market SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F U.S. OTCQB
Published on 10/28/2026 at 08:00, 1 minute ago Algo Grande Copper Makes New Skarn Discovery at Adelita; Step-Out Hole AG-CG-PH2-003 Returns a Combined 139.81 Metres of 1.3% CuEq from Cerro Grande and the New Margarita Skarn
Published on 10/28/2026 at 02:55, 5 hours 6 minutes ago Challenger Underground MRE Doubles to 230koz @ 3.65 g/t Au
Published on 10/28/2026 at 02:50, 5 hours 11 minutes ago Letter to Shareholders Regarding Annual General Meeting
Published on 10/27/2026 at 23:40, 8 hours 21 minutes ago Second Closing of US$3.4 Million Private Placement
Published on 10/27/2026 at 23:25, 8 hours 36 minutes ago Gamma Resources Announces Leadership Transition: C. Connor Messler to Become Chief Executive Officer and Gabriel Alonso-Mendoza to Become Chairman; Grants Incentive Stock Options
Published on 10/28/2026 at 07:42, 19 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: 2026 Annual General Meeting results
Published on 10/28/2026 at 07:32, 28 minutes ago Correction: PALFINGER sharpens portfolio and risk profile, strengthening focus, profitability and resilience in the third quarter 2026
Published on 10/28/2026 at 07:30, 31 minutes ago Media Release: Sensirion announces global availability of the single-use SFM3304-D for proximal flow measurement in mechanical ventilation
Published on 10/28/2026 at 07:30, 31 minutes ago Delivery Hero hits one billion orders in Q3 as growth accelerates further, raises full-year guidance
Published on 10/28/2026 at 07:30, 31 minutes ago Symrise delivered strong volume-driven organic sales growth in Q3 2026 and reaffirms full-year outlook
Published on 10/27/2026 at 18:00, 14 hours 1 minute ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 14 hours 1 minute ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
